VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarterProceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to...
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
Oss, The Netherlands, July 2, 2020 —Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure(including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOMBrabant Ventures, BrightGene and...
Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer
Amsterdam, The Netherlands, 1 July 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that Dr C....
BioGeneration Ventures closes BGV IV fund at €105 million
Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq Investment focus on entrepreneurial innovation in therapeutics in Europe Total assets under management >€220 million ($250m) Naarden, The...
Scenic Biotech Awarded €3.1 million Innovation Credit from Dutch Government to Progress CD47/QPCTL Immuno-oncology Program
Amsterdam, The Netherlands, 23 June 2020 - Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has...
Dutch Mellon Medical teaming up with MedTech designer Demcon to further advance major innovation in surgical single-handed suturing using the Switch®, supported by new financing.
Abdominal suturing tests show that the Switch® facilitates the use of ‘small-bites’ technique for sustainable abdominal wall closure, preventing incisional hernia Study in The Lancet[1] by investigators from Erasmus MC Rotterdam showing ‘small bites’ should become the...
Azafaros expands executive management team and operations
• Company attracts three experienced industry executives to lead preclinical and clinical development as well as finance and operations• Company incorporates Swiss subsidiary and gains additional investment from Schroder Adveq Leiden, The Netherlands, June 10th, 2020...
Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director
Ghent, Belgium – June 10, 2020 - Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and development leadership...
Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer
--New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates-- Ghent, Belgium – June 3, 2020 - Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the...
Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline.
Financing round led by Forbion with participation from BioMedPartners and founding investor BioGeneration Ventures Leiden, The Netherlands, February 6th, 2020 – Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million...